Zavante is a late clinical-stage biopharmaceutical company focused on licensing, developing and commercializing novel products that address serious unmet medical needs in the hospital.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 03/30/16 | $45,000,000 | Series A |
Aisling Capital Frazier Healthcare Longitude Capital | undisclosed |
